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Pharmacogenetics, the study of the influ-
ence of genetic variation on drug response, 
and pharmacogenomics, the genome-wide 
and multifactorial extension of the term 
(the inclusive code PGx is used from here 
on), are central to the modern concept of 
personalized medicine. Although a “person-
alized” approach has always been a hallmark 
of good medical practice, the new aspect is 
the extensive use of molecular data to tailor 
drug therapy to the individual patient, in 
order to maximize therapeutic benefit and 
to minimize adverse events. PGx developed 
as an academic discipline over the past six 
decades, during which a significant amount 
of astounding examples for pharmacologi-
cally relevant genotype-phenotype relation-
ships have been worked out. Basic principles 
were established, technologies developed, 
and dozens of genes characterized that have 
to do with absorption, distribution, metab-
olism, and excretion (ADME) of drugs, but 
also receptors and other drug targets.
Only during the past decade first serious 
attempts have been made to translate this 
knowledge into clinical practice. Rather 
suddenly,  it  became  clear  that  transla-
tion is everything but easy. The reasons 
for these problems are manifold. It will 
require deeper scientific advances in vari-
ous directions but also concerted medical, 
regulatory and social actions to realize the 
opportunities of PGx for better medical 
treatment.
PGx is nurtured by two major streams of 
research, a basic one that aims to discover 
genetic variation and to understand biologi-
cal genotype–phenotype correlations, and 
a clinically oriented one that builds up on 
basic knowledge to investigate genetic fac-
tors in relation to drug response phenotypes 
and to apply novel diagnostic tools to trans-
late this into clinical care. Modern technol-
ogy has revolutionized the speed and output 
of molecular discovery, providing us with 
new armament for research. Undoubtedly 
this  will  open  up  great  opportunities. 
However, great challenges must be met in 
order to realize this potential for basic and 
clinical PGx.
 Challenges in basiC researCh
In basic PGx we would like to understand 
how genetic variation contributes to biolog-
ical phenotypic variation. Over 300 ADME 
genes and even more drug target genes have 
been identified in the human genome1. Only 
few of these have so far been systematically 
investigated, but even for the well character-
ized CYP, UGT, or some drug transporter 
genes, our knowledge is often fragmentary 
regarding both genetic and phenotypic vari-
ation. The current large-scale endeavors like 
the 1000-genomes project will uncover the 
existing genetic variation in all our genes 
across various racial groups within a few 
years. However the major task will be to find 
out what these myriads of SNPs and struc-
tural variants have to do with our health 
and  variable  response  to  drugs.  Genetic 
alterations can influence gene expression 
in far more intricate ways than commonly 
thought, and multiple effects on various lev-
els may turn out to be the rule rather than 
the exception. To elucidate at least the major 
functional variants of each gene is precondi-
tion for developing diagnostic tools, select 
relevant variants for pharmacogenetic stud-
ies,  and  correctly  interpret  associations. 
Challenges here include improvement of 
in silico prediction tools and in vitro test 
systems, which often lead to controversial 
unreproducible data, but also development 
of large collaborative biobanks with exten-
sive medical sample information available 
to researchers on request to study genotype–
phenotype relationships.
Much of the genetic heritability appears 
to be hidden in multigenic and multifacto-
rial complex traits. Important genes such 
as CYP1A2 or CYP3A4 and probably the 
majority of all genes may lack predictive 
variants. Yet twin studies as well as recent 
genome-wide association studies (GWAS) 
suggest a high proportion of genetic con-
tribution  to  quantitative  (e.g.,  expres-
sion, enzyme activity) phenotypes, which 
implies the existence of multiple trans- and 
other complex types of interactions. It is 
  currently unclear which strategies could be 
most successful to tackle these problems. 
  Pathway-oriented approaches are appeal-
ing  because  they  are  hypothesis-driven. 
However  their  limitation  is  the  lack  of 
knowledge about biological gene networks. 
GWA allows hypothesis-free identification 
of cis- and trans- genetic determinants and 
can in principle capture the entire heritabil-
ity of almost any phenotype. Current limita-
tions concern incomplete and inappropriate 
SNP-coverage (lack of causative mutations, 
difficulties with pseudogenes, etc.) as well 
as  appropriate  statistical    methods  for 
  elucidating the “hidden heritability” behind 
the most significant associations that sur-
vive multiple testing correction.
Nevertheless,  the  novel  technologies 
already and undoubtedly will continue to 
fuel basic research with big challenges, as 
it will become very important to function-
ally validate a plethora of new findings and 
hypotheses.
A helpful hand to contribute to enhanced 
understanding of complex biological net-
works should be expected from systems biol-
ogy modeling approaches. Although still in 
its infancy regarding eukaryotes and higher 
animal biology, there is no doubt that more 
mechanistic  and  quantitative  models  of 
biological networks will be required to bet-
ter understand the role of individual genes 
and their variants in the context of health, 
disease, and treatment. The challenge here is 
to develop, together with systems biologists, 
modeling frameworks for bottom-up and 
top–down approaches that are adapted to 
the special requirements and characteristics 
of PGx research. These include particularly 
difficult experimental settings (human hepa-
tocytes,  tissue  collections,  clinical  studies 
including healthy volunteers and patients) 
as well as theoretical challenges, e.g., how 
to integrate interindividual and population 
variation into system biology concepts.
Further challenges in basic research con-
cern a variety of additional influential factors 
that need to be addressed more systematically. 
Genetic variation is only one side of the coin: 
we need to know the influence of   numerous  1http://www.pharmgkb.org/Zanger  Challenges and opportunities in pharmacogenetics
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mentioned  above.  Particular  limitations 
for pharmacogenetic GWA studies include 
small sample sizes due to rare adverse drug 
  reactions and the difficulty of replication, 
lack of rare or even less common (<5%) vari-
ants on the microarrays, and heterogeneity of 
drug response phenotype. There are however 
solutions to these problems already in sight: 
establishment of multinational consortia, as 
currently being pursued in several areas, and 
of national health care system programs to 
systematically collect and document drug 
response phenotypes will help to overcome 
sample  size  limitations  at  least  partially; 
analysis of rare variants will be possible by 
next generation sequencing or by the advent 
of the “personal genome” at reasonable cost; 
better definition of drug response phenotype 
could be possible by collecting additional 
high-density  metabolomic  or  proteomic 
data. In addition, the multifactorial nature 
of drug response phenotypes will require 
novel strategies to detect complex genetic 
influences  from  multiple  minor  impact 
genes, entire pathways, or gene–gene and 
gene–environment interactions, a hot topic 
area already.
Frontiers  in  Pharmacogenetics  is  an 
open-access platform for the publication 
of research papers that address any of the 
above mentioned topics. We welcome sub-
mission  of  manuscripts  that  report  new 
scientific discoveries of basic, clinical, and 
applied PGx research, as well as other papers 
that present new ideas, discuss timely issues, 
or report the essence of scientific meetings. 
The open access policy of Frontiers in... will 
contribute to make science available not 
only to scientists but to everyone interested 
or concerned, be it a patient, physician, stu-
dent, nurse, teacher, health care officer, or 
just any interested person. In this sense, 
Frontiers  in  Pharmacogenetics  can  –  and 
hopefully will – help to advance PGx and 
personalized medicine.
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pump inhibitors, CYP2D6 and tamoxifen, 
or  CYP2B6  and  efavirenz.  In  addition  to 
well-designed and large enough prospective 
studies, development of more advanced algo-
rithms that can take additional genetic pre-
dictors and confounding factors into account 
and deliver quantitative test-data which can 
be better compared among different studies 
and with other routinely applied clinical tests 
(which are often not better regarding their 
test parameters compared to PGx tests) could 
help to demonstrate clinical utility.
In addition to these realistic examples, 
a big challenge in clinical research will be 
to  fill  up  the  PGx  pipeline  with  further 
successful demonstrations of clinical sig-
nificance, in order to sustain the develop-
ment of reliable and cheap enough tests for 
routine application by the industry, and to 
continue to motivate other players from 
industry, health care systems, and regula-
tors to come (or stay) on board and further 
develop clinical translation.
So, how to fill up the pipeline? Common 
problems are that pronounced pharmacoki-
netic effects observed do not affect clinical 
endpoints, as is the case, for example, for 
several CNS drugs metabolized by phar-
macogenetic  enzymes  like  CYP2D6  or 
CYP2C19. In addition, reports of clinical 
significance are often difficult to validate. 
Better definition of clinical phenotypes and 
endpoints, and development of standards 
for clinical PGx studies regarding power, 
consideration of confounding factors, and 
test statistics may be required to demon-
strate clinical utility in such cases.
Beyond the classical PGx targets, entirely 
novel discoveries can be made by the GWA 
technology,  which  has  been  firmly  estab-
lished within the past 5 years by showing 
that highly significant genetic determinants 
for various phenotypes can be reproducibly 
identified3. Several recent studies on phar-
macological drug response phenotypes (e.g., 
IL28B and response to hepatitis C interferon-
alpha and ribavirin, HLA-B*5701, and drug-
induced  liver  injury  due  to  flucloxacillin, 
IL15 and risk of minimal residual disease in 
childhood  acute  lymphoblastic  leukemia) 
now suggest that GWA could be highly suc-
cessful also in the PGx context, because asso-
ciations found in well-designed studies are of 
immediate clinical significance. Nevertheless, 
there are several challenges, in part already 
non-genetic  end  environmental  factors, 
including sex, age, diet, lifestyle, and our intes-
tinal microflora, to name just a few influen-
tial factors for PGx. Furthermore, epigenetic 
changes, in contrast to the static nature of 
DNA sequence variants, can influence expres-
sion patterns in a time-, environment- and 
tissue-dependent manner. Circadian rhythms 
markedly change gene expression patterns of 
many ADME genes thereby affecting phar-
macokinetics and drug response in a time-
dependent  manner.  Exploration  of  these 
phenomena and their genetic determinants 
has just begun,   especially in humans. A huge 
scale of molecular data sets will become avail-
able on all these aspects. However, the practi-
cal, conceptual, and computational problems 
of integrating these data is yet another signifi-
cant challenge before their full opportunities 
can be exploited.
Challenges in CliniCal researCh
As it comes to clinical translation, PGx is 
faced  with  big  hopes  and  high  expecta-
tions by everybody involved: patients who 
demand effective treatment free of adverse 
effects; physicians in need of guidance for 
selecting  the  most  appropriate  drug  and 
the right dose for the patient; health care 
providers who have to find ways to improve 
medical care while reducing cost at the same 
time; regulatory agencies who need proof 
of concept to issue guidelines and laws, and 
also drug developers who are in fear of losing 
their costly drug candidates due to unfore-
seen toxicity in late stages of development.
More than 200 drug labels in the US, cor-
responding to about 10% of drugs approved 
by the FDA, contain pharmacogenetic infor-
mation, still a relatively small figure. But it 
shows that a significant number of relation-
ships between genetic markers and pharma-
cokinetic or drug response phenotypes are 
potentially relevant. However, only very few 
of them are currently used for individual-
ized treatment, e.g., trastuzumab for HER2 
overexpressing breast cancer and some other 
anticancer agents, and more recently HLA-
B*5701 testing to avoid abacavir hypersen-
sitivity2. Data proving that genotyping can 
successfully  guide  treatment  decisions  is 
still largely lacking or controversial, even for 
well-investigated examples such as TPMT 
and  thiopurines,  CYP2C19,  and  proton 
2http://www.fda.gov/Drugs/ScienceResearch/Resear-
chAreas/Pharmacogenetics/ucm083378.htm 3http://www.genome.gov/gwastudies/